|
Among all incident breast cancers (N = 1247)
|
|
Sex
|
100
|
Male
|
12 (1.0)
|
|
Female
|
1232 (99.0)
|
|
Invasiveness in women
|
100
|
Non-invasive
|
19 (1.5)
|
|
Invasive
|
1216 (98.5)
|
|
Among invasive incident breast cancers in women (N = 1216)
|
|
Ethnicity
|
99.4
|
Black
|
1,092 (90.3)
|
|
White
|
49 (4.1)
|
|
Colored
|
46 (3.8)
|
|
Asian
|
22 (1.8)
|
|
Age at diagnosis (years)
| |
<40
|
182 (15.0)
|
|
40–49
|
290 (23.9)
|
|
50–59
|
310 (25.5)
|
|
60–69
|
221 (18.2)
|
|
70–79
|
147 (12.1)
|
|
≥80
|
66 (5.4)
|
|
Year of diagnosis
|
100
|
2006–2007
|
172 (14.1)
|
|
2008–2009
|
431 (35.4)
|
|
2010–2012
|
613 (50.4)
|
|
HIV status
|
69.0
|
Negative
|
686 (81.8)
|
|
Positive
|
153 (18.2)
|
|
Stage
|
98.1
|
I
|
61 (5.1)
|
|
IIA
|
211 (17.7)
|
|
IIB
|
280 (23.5)
|
|
IIIA
|
148 (12.4)
|
|
IIIB-IIIC
|
385 (32.3)
|
|
IV metastases
|
107 (9.0)
|
|
Tumor grade
|
80.0
|
1 = Well-differentiated
|
106 (10.9)
|
|
2 = Moderately-differentiated
|
455 (46.8)
|
|
3 = Poorly-differentiated
|
412 (42.3)
|
|
ER
|
88.2
|
Negative
|
376 (35.1)
|
|
Positive: of which
|
696 (64.9)
|
|
Positive stain score +1
|
96
|
|
+2
|
155
|
|
+3
|
445
|
|
PR
|
87.8
|
Negative
|
500 (46.9)
|
|
Positive, of which:
|
567 (53.1)
|
|
Positive staining score +1
|
111
|
|
+2
|
163
|
|
+3
|
293
|
|
HER2
|
84.9
|
Negative, of which:
|
762 (74.1)
|
|
Negative stain score 0
|
404
|
|
+1
|
142
|
|
+2
|
216
|
|
Positive (+3)
|
267 (26.0)
|
|
Subtypes abbreviations:
|
84.5
|
Luminal A (ERP and/or PRP, HER2N)
|
551 (53.7)
|
|
Luminal B (ERP and/or PRP, HER2P)
|
150 (14.6)
|
|
HER2P enriched (ERN, PRN, HER2P)
|
117 (11.04)
|
|
Triple negative (ERN, PRN, HER2N)
|
209 (20.4)
|
